Merck, Eisai Provide Update On Phase 3 LEAP-010 Trial Evaluating KEYTRUDA Plus LENVIMA; Combination Did Not Result In An Overall Survival Benefit For Patients
Portfolio Pulse from Benzinga Newsdesk
Merck and Eisai have announced that their Phase 3 LEAP-010 trial evaluating KEYTRUDA plus LENVIMA did not result in an overall survival benefit for patients. The study will be closed due to the low likelihood of reaching the protocol-specified threshold for statistical significance.
August 25, 2023 | 10:19 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eisai's collaboration with Merck on the KEYTRUDA plus LENVIMA trial did not yield the expected results, leading to the closure of the study.
The unsuccessful trial results could negatively impact Eisai's stock in the short term as it represents a failure in one of the company's collaborative efforts.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Merck's KEYTRUDA plus LENVIMA trial did not meet its primary endpoint, leading to the closure of the study.
The failure of the trial to meet its primary endpoint could negatively impact Merck's stock in the short term as it indicates a setback in the company's product pipeline.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100